CORDIS
EU research results

CORDIS

English EN
Alphaviral Immunotherapy against Glioblastoma

Alphaviral Immunotherapy against Glioblastoma

Objective

Alphaviral Immunotherapy against Glioblastoma

Glioblastomas (GBM) are the most frequent type of primary brain tumours with no treatment or cure available. Despite the current standard care, GBMs remain 100% fatal with median survival of patients for only 12 - 15 months. Thus, there is an urgent need for novel effective therapies.
Among the emerging new therapeutic approaches is oncolytic virotherapy with replicative viruses that kill cancer cells. During his PhD studies, the applicant researcher, Miika Martikainen, has engineered novel tumour-targeted replicative alphavirus that shows promising therapeutic response in a syngeneic orthotropic mouse model for human GBM. As the next step, the applicant seeks to join Professor Magnus Essand’s group at the Uppsala University to conduct his postdoctoral research project that aims to development of clinically relevant oncolytic immunovirotherapy against GBM.
To achieve this aim, previously unappreciated potency of Alphaviral oncolytic virotherapy is combined with synergistic immunotherapy with dendritic cell vaccination and/or adenoviruses. A detailed analysis of relevant immune responses associated with the therapy efficacy will be conducted to allow clinical translation of the results. The state-of-the-art methods available and the training received during the fellowship at host laboratory and secondments will arm the applicant with the skills and knowledge that allow him to establish a career as independent research scientist in a field that aims to develop novel ways to treat severe forms cancer.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

UPPSALA UNIVERSITET

Address

Von Kraemers Alle 4
751 05 Uppsala

Sweden

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 185 857,20

Project information

Grant agreement ID: 707093

Status

Closed project

  • Start date

    1 May 2016

  • End date

    30 April 2018

Funded under:

H2020-EU.1.3.2.

  • Overall budget:

    € 185 857,20

  • EU contribution

    € 185 857,20

Coordinated by:

UPPSALA UNIVERSITET

Sweden